- Home
- FLYE vs ADVM Comparison
FLYE vs ADVM Comparison
Compare FLYE & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- ADVM
- Stock Information
- Founded
- FLYE 2018
- ADVM 2006
- Country
- FLYE United States
- ADVM United States
- Employees
- FLYE N/A
- ADVM N/A
- Industry
- FLYE Aerospace
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLYE Industrials
- ADVM Health Care
- Exchange
- FLYE Nasdaq
- ADVM Nasdaq
- Market Cap
- FLYE 91.6M
- ADVM 94.6M
- IPO Year
- FLYE 2024
- ADVM 2014
- Fundamental
- Price
- FLYE $0.56
- ADVM $4.59
- Analyst Decision
- FLYE
- ADVM Strong Buy
- Analyst Count
- FLYE 0
- ADVM 4
- Target Price
- FLYE N/A
- ADVM $19.75
- AVG Volume (30 Days)
- FLYE 636.1K
- ADVM 791.9K
- Earning Date
- FLYE 11-18-2025
- ADVM 11-03-2025
- Dividend Yield
- FLYE N/A
- ADVM N/A
- EPS Growth
- FLYE N/A
- ADVM N/A
- EPS
- FLYE N/A
- ADVM N/A
- Revenue
- FLYE $22,881,935.00
- ADVM $1,000,000.00
- Revenue This Year
- FLYE N/A
- ADVM $1,449.40
- Revenue Next Year
- FLYE N/A
- ADVM N/A
- P/E Ratio
- FLYE N/A
- ADVM N/A
- Revenue Growth
- FLYE N/A
- ADVM N/A
- 52 Week Low
- FLYE $0.51
- ADVM $1.78
- 52 Week High
- FLYE $8.30
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- FLYE 31.29
- ADVM 52.89
- Support Level
- FLYE $0.64
- ADVM $4.72
- Resistance Level
- FLYE $0.72
- ADVM $5.59
- Average True Range (ATR)
- FLYE 0.06
- ADVM 0.52
- MACD
- FLYE 0.06
- ADVM -0.08
- Stochastic Oscillator
- FLYE 2.39
- ADVM 26.30
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.